Literature DB >> 10230581

A risk-benefit assessment of oxytocics in obstetric practice.

M Winkler1, W Rath.   

Abstract

Substances that stimulate contractions of the myometrium have found wide applications in present day obstetrics. Above all, fully synthetic, uterus-selective prostaglandin analogues are used for preoperative priming of the cervix for termination of pregnancies in the first trimester as well as for the induction of abortions in the second trimester and have proved to have a much higher efficacy than oxytocin. Because of the pharmacological synergism of their cervix ripening and myometrium stimulating activities, the local use of natural prostaglandin E2 preparations (used intracervically as a gel or vaginally as a gel or as a tablet) is unequivocally superior to use of oxytocin with its almost exclusive contraction stimulating activity for induction of labour, especially for women with an unripe cervix. In women with a ripe cervix, oxytocin and prostaglandins are equally effective with oxytocin having the major advantage of its better controllability on continuous intravenous infusion (plasma elimination half-life of 10 minutes). Over the past 50 years, the use of oxytocin and ergot alkaloids preparations as prophylaxis against postpartum atonia has led to a marked reduction in maternal deaths. The same is true to a major extent for therapy for uterine atonia where the intravenous infusion of dinoprost is an indispensable and life-saving procedure after the failure of systemic administration of oxytocin or ergot alkaloid preparations. On the other hand, the administration of oxytocics can be accompanied by a wide range of adverse systemic and uterine effects and complications ranging from severe cardiovascular incidents with a fatal outcome through to the threat of uterine hyperstimulation with fetal asphyxia to uterine rupture. For these reasons, an adequate knowledge of the pharmacokinetics as well as the systemic and uterine activities and adverse effects of these substances is an essential prerequisite for every physician in evaluating differential indications for their use and adequate monitoring for mother and infant. Of particular importance is the use of prostaglandins for cervical priming prior to termination of pregnancies in the first and second trimesters and the use of native prostaglandin and oxytocin for inducing delivery in cases of fetal deaths as well as vital infants. Both substances play a decisive role at the beginning of delivery. Cervical priming and induction of contractions would not be conceivable without prostaglandin and oxytocin. The pharmacological properties of the 2 substances can be used in different ways for the induction of delivery. Oxytocin ergot alkaloids and prostaglandin are essential for the management of postpartum uterine atonia where their use often represents a decisive, life-saving intervention.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10230581     DOI: 10.2165/00002018-199920040-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  96 in total

1.  Cardiac arrest following intramyometrial injection of prostaglandin E2.

Authors:  M T Popat; N Suppiah; J B White
Journal:  Anaesthesia       Date:  1991-03       Impact factor: 6.955

2.  Misoprostol for third stage of labour.

Authors:  H el-Refaey; P O'Brien; W Morafa; J Walder; C Rodeck
Journal:  Lancet       Date:  1996-05-04       Impact factor: 79.321

3.  [Termination of pregnancy in the 2nd trimester by serial administration of gemeprost vaginal suppositories. A prospective study (corrected)].

Authors:  T Krauss; W Rath; T Cunze
Journal:  Geburtshilfe Frauenheilkd       Date:  1994-11       Impact factor: 2.915

Review 4.  Choice of oxytocic preparation for routine use in the management of the third stage of labour: an overview of the evidence from controlled trials.

Authors:  D Elbourne; W Prendiville; I Chalmers
Journal:  Br J Obstet Gynaecol       Date:  1988-01

5.  Prostaglandin receptors in the human, monkey and hamster uterus.

Authors:  A E Wakeling; L J Wyngarden
Journal:  Endocrinology       Date:  1974-07       Impact factor: 4.736

6.  [Premature termination of pregnancy in the 2nd and 3rd trimester. Serial administration of 1 mg gemeprost vaginal suppositories versus intravenous sulproston].

Authors:  T Müller; J Backe; A Rempen
Journal:  Geburtshilfe Frauenheilkd       Date:  1996-05       Impact factor: 2.915

Review 7.  [Principles of physiologic and drug-induced cervix ripening--recent morphologic and biochemical findings].

Authors:  W Rath; R Osmers; B C Adelmann-Grill; H W Stuhlsatz; H Tschesche; M Szevérini
Journal:  Geburtshilfe Frauenheilkd       Date:  1990-09       Impact factor: 2.915

8.  [Gemeprost vaginal suppositories versus intracervical sulprostone gel administration for cervic priming in the 1st trimester. A tonometric controlled comparative study].

Authors:  D Kulenkampff; W Rath; W Kuhn
Journal:  Geburtshilfe Frauenheilkd       Date:  1994-03       Impact factor: 2.915

9.  A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy.

Authors:  J K Jain; D R Mishell
Journal:  N Engl J Med       Date:  1994-08-04       Impact factor: 91.245

Review 10.  Third-trimester uterine rupture after prostaglandin E2 use for labor induction.

Authors:  R Maymon; L Haimovich; A Shulman; M Pomeranz; M Holtzinger; C Bahary
Journal:  J Reprod Med       Date:  1992-05       Impact factor: 0.142

View more
  1 in total

Review 1.  The peripheral chemoreflex: indefatigable guardian of fetal physiological adaptation to labour.

Authors:  Christopher A Lear; Guido Wassink; Jenny A Westgate; Jan G Nijhuis; Austin Ugwumadu; Robert Galinsky; Laura Bennet; Alistair J Gunn
Journal:  J Physiol       Date:  2018-04-26       Impact factor: 5.182

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.